An experimental Covid-19 vaccine from Novavax Inc. was 90.4% efficient at stopping symptomatic illness in adults in a big medical trial, the corporate stated, outcomes that transfer the shot a step nearer to international use.
The 29,960-person examine carried out within the U.S. and Mexico additionally discovered that the vaccine was equally efficient in opposition to newer coronavirus strains, particularly the alpha variant now dominant within the U.S., Novavax stated.
The vaccine, given in two doses three weeks aside, was additionally usually secure and properly tolerated within the examine, the corporate stated.
“Our vaccine works very properly although the virus has mutated considerably,” stated Dr. Gregory Glenn, Novavax’s president of analysis and improvement.
Altogether, the outcomes counsel Novavax’s vaccine is on monitor to turn out to be the fourth approved to be used within the U.S. But Novavax executives stated the regulatory clearances are months away as a result of